Clinical Studies

Review evidence demonstrating the impact continuous glucose monitoring (CGM) use can have on glycemic control and variability.

 


 

Evidence for Benefits of CGM Use

Recognized as a standard of care in diabetes management by the American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE) and the Endocrine Society,1,2,3 continuous glucose monitoring (CGM) use has proven to both reduce A1C and time spent in hypoglycemia regardless of delivery method.4,5 Regular CGM use is also associated with an increase of time spent in range,4,6 a reduction of severe hypoglycemic incidents,7,8 and associated with many behavioral changes that promote significant positive change in diabetes self-management.9

Image
Patient Info Form

1 American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55-S64. 

2 Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. Endocr Pract. 2016;22(2):231-261. 

3 Peters A, Ahmann A, Battelino T et al. Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016:jc.2016-2534. 

4 Šoupal J, Petruželková L, Flekač M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538. 

5 Battelino T PM, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes. Diabetes Care. 2011;34(4):795-800. 

6 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA. 2017; 317(4); 371-378. 

7 Choudhary P, Ramasamy S, Green L et al. Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care. 2013;36(12):4160-4162. 

8 Lind M, Polonsky, W, Hirsch, I, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Injections – The GOLD Randomized Clinical Trial. [published January 2017]. JAMA. 

9 Haas L, Maryniuk M, Beck J, et al. National Standards for Diabetes Self-Management Education and Support, Diabetes Care, Volume 35, November 2012 

Contact Us

If you are a healthcare provider and want to learn more about Dexcom, please fill out the form and a representative will contact you. If you are a Dexcom User or Patient, please contact Dexcom here.

 

By choosing to request info, you are granting Dexcom, Inc. permission to process your personal information to send you additional information and promotional communications related to Dexcom products. You may opt-out of these communications at any time. Dexcom respects the privacy and confidentiality of your personal information. The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.